Skip to main content

Table 3 (Chemo-)radiation treatment details

From: Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

  Radiation target volumes Radiation dose Boost / Elective fields Chemotherapy
NSCLC trial Primary lung tumour and involved regional lymph nodes 66 Gy in 24 fractions N.A. Cisplatin 6 mg/m2 1.5–2 h before radiation on every radiotherapy day#
Breast cancer trial Whole breast and involved regional lymph node areas 46.69 Gy in 23 fractions SIB of 14.49 Gy in 23 fractions to macroscopic tumour in breast; sequential boost of 10 Gy in 5 fractions to macroscopic lymph nodes (only if applicable) N.A.
HNSCC trial Primary tumour and regional metastatic lymph nodes; elective lymph node volumes based on site of primary tumour and stage 70 Gy in 35 fractions Elective fields: 46 Gy in 23 fractions (sequential boost technique) or 54.25 Gy in 35 fractions (SIB technique) N.A.
  1. # in the CCRT arm only. Gy = Gray. N.A. = not applicable, SIB = simultaneous integrated boost